Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
STU:RPD: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany IPO Date
2021-08-26Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 1.17 | |||||
Debt-to-EBITDA | 6.25 | |||||
Interest Coverage | 5.15 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.67 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.6 | |||||
3-Year EBITDA Growth Rate | -14.5 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | -2.9 | |||||
3-Year Book Growth Rate | 5.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 31.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.29 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 73.43 | |||||
9-Day RSI | 60.5 | |||||
14-Day RSI | 55.72 | |||||
6-1 Month Momentum % | -8.32 | |||||
12-1 Month Momentum % | -5.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.35 | |||||
Quick Ratio | 9.35 | |||||
Cash Ratio | 9.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.99 | |||||
Dividend Payout Ratio | 0.75 | |||||
3-Year Dividend Growth Rate | 38.7 | |||||
Forward Dividend Yield % | 2.99 | |||||
5-Year Yield-on-Cost % | 2.99 | |||||
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | 7.78 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 42.91 | |||||
Net Margin % | 30.09 | |||||
FCF Margin % | 119.22 | |||||
ROE % | 10.54 | |||||
ROA % | 4.05 | |||||
ROIC % | 6.47 | |||||
ROCE % | 7.48 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.94 | |||||
Forward PE Ratio | 7.02 | |||||
PE Ratio without NRI | 25.9 | |||||
PS Ratio | 7.6 | |||||
PB Ratio | 1.97 | |||||
Price-to-Tangible-Book | 1.97 | |||||
Price-to-Free-Cash-Flow | 6.37 | |||||
Price-to-Operating-Cash-Flow | 6.37 | |||||
EV-to-EBIT | 14.69 | |||||
EV-to-Forward-EBIT | 9.76 | |||||
EV-to-EBITDA | 14.69 | |||||
EV-to-Forward-EBITDA | 9.76 | |||||
EV-to-Revenue | 7.99 | |||||
EV-to-Forward-Revenue | 6.95 | |||||
EV-to-FCF | 6.66 | |||||
Price-to-Graham-Number | 1.51 | |||||
Earnings Yield (Greenblatt) % | 6.81 | |||||
FCF Yield % | 20.84 | |||||
Forward Rate of Return (Yacktman) % | -16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,070.78 | ||
EPS (TTM) (€) | 1.382 | ||
Beta | 0 | ||
Volatility % | 17.94 | ||
14-Day RSI | 55.72 | ||
14-Day ATR (€) | 0.416913 | ||
20-Day SMA (€) | 24.9675 | ||
12-1 Month Momentum % | -5.92 | ||
52-Week Range (€) | 23.44 - 30 | ||
Shares Outstanding (Mil) | 448.13 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Royalty Pharma PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(STU:RPD)'s stock price today?
The current price of STU:RPD is €25.45. The 52 week high of STU:RPD is €30.00 and 52 week low is €23.44.
When is next earnings date of Royalty Pharma PLC(STU:RPD)?
The next earnings date of Royalty Pharma PLC(STU:RPD) is .
Does Royalty Pharma PLC(STU:RPD) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(STU:RPD) is 2.99% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(STU:RPD) was 0.75. The lowest was 0.33. And the median was 0.41. The  Forward Dividend Yield % of Royalty Pharma PLC(STU:RPD) is 2.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |